January 8, 2018 / 6:52 PM / in a year

BRIEF-Sarepta Therapeutics Provides FY 2018 Rev Forecast For Exondys 51

Jan 8 (Reuters) - Sarepta Therapeutics Inc:

* SAREPTA THERAPEUTICS PRE-ANNOUNCES FOURTH QUARTER 2017 REVENUE AND PROVIDES FULL-YEAR 2018 REVENUE GUIDANCE FOR EXONDYS 51® (ETEPLIRSEN), REPRESENTING APPROXIMATELY 100 PERCENT YEAR-OVER-YEAR GROWTH

* Q4 REVENUE $57.3 MILLION VERSUS I/B/E/S VIEW $55.8 MILLION

* SEES FY 2018 REVENUE $295 MILLION TO $305 MILLION

* SAYS FULL-YEAR 2018 EXONDYS 51 REVENUE GUIDANCE OF $295 - $305 MILLION

* SAYS ‍FULL-YEAR 2017 EXONDYS 51 UNAUDITED REVENUE OF $154.6 MILLION​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below